Sound Shore posted 20 year annualized returns of 7.30% and 7.51% for its Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX), respectively......
(read more)May 13 - Hedge Funds, News - Comments
CSRA Inc (NYSE:CSRA) (Bloomberg) General Dynamics Corp., the maker of Abrams tanks and nuclear submarines, is making a record bet on reinvigorating its......
(read more)February 12 - Market Movers, News - Comments
1. U.S. Stock Market: “U.S. equities traded higher on Wednesday as investors cheered the Federal Reserve’s plan for scaling back its massive......
(read more)May 24 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech - Comments
1. U.S. Stock Market: “The S&P 500 traded higher on Tuesday and nearly erased the losses suffered from the biggest sell-off of the year......
(read more)May 23 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has had another misfortune in the UK. The country’s public health watchdog, NICE (the National Institute......
(read more)February 17 - News, Stock Analysis - Comments
Which are the most successful innovative companies in the world in 2016? Bringing something new to the table is something that seems to be difficult these......
(read more)October 26 - Hedge Funds, Lists, News - Comments
Crude futures are in the red today as sentiment around the commodity cools off. Meanwhile the Dow, Nasdaq, and S&P 500 are relatively flat as traders......
(read more)July 28 - Market Movers, News - Comments
U.S stocks have edged higher on Tuesday following a rise in oil prices and Fed Chairwoman Janet Yellen’s speech on Monday, in which she maintained an......
(read more)June 7 - Market Movers, News - Comments
While several hedge funds have suffered enormous losses this year due to their investments in biotech stocks, the performance of the leading biotech-focused......
(read more)May 7 - Hedge Fund Analysis, Hedge Funds, News - Comments
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker. The firm focuses on life science and biotechnology companies......
(read more)February 25 - Hedge Funds, News - Comments
Professional money managers are quick to judge when things start to turn sour for a particular company. Generally, it would do retail investors well ......
(read more)December 11 - Hedge Funds, News - Comments
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today. It was founded in 2000 by brothers Julian Baker......
(read more)December 9 - Hedge Fund Analysis, Hedge Funds, News - Comments
Mariner Investment Group is a New York-based investment advisory firm founded by William Michaelcheck in 1992. Apart from its headquarters in New York......
(read more)November 13 - Hedge Fund Analysis, Hedge Funds, News - Comments
At Insider Monkey, we track over 700 hedge funds and investment companies, which allows us to understand the market sentiment towards any given stock.......
(read more)August 17 - Hedge Fund Analysis, Hedge Funds, News - Comments
With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker‘s Baker Bros. Advisors is making a habit of hitting......
(read more)July 10 - Hedge Funds, News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Baxter International Inc (NYSE:BAX), and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) are among the top healthcare......
(read more)June 30 - Hedge Funds, News - Comments
Orphan drugs, those treating rare conditions for small segments of the population, do not normally get much attention compared with the likes of a $12......
(read more)October 11 - Hedge Funds, News - Comments
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur. The best way to protect yourself is to be logical when......
(read more)September 16 - News - Comments
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has priced its Gattex drug for short bowel syndrome, or SBS, at $295,000, expecting to make peak sales of $350......
(read more)September 11 - News - Comments
A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has......
(read more)September 9 - News - Comments
Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a good investment? If you were to ask many investors, hedge funds are viewed as delayed, outdated investment......
(read more)August 29 - News - Comments
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a buy? In the 21st century investor’s toolkit, there are tons of metrics market participants can......
(read more)August 26 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) investors are standing pat. In the 21st century investor’s toolkit, there are dozens of indicators investors......
(read more)August 26 - News - Comments
Who’s buying Amgen, Inc. (NASDAQ:AMGN)? To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the......
(read more)August 25 - News - Comments
Biogen Idec Inc. (NASDAQ:BIIB) investors: listen up. To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten......
(read more)August 23 - News - Comments
Will Celgene Corporation (NASDAQ:CELG) burn you? Here’s some data to help answer that question. To many traders, hedge funds are perceived as overrated......
(read more)August 22 - News - Comments
At some point, a company reaches a level of maximum valuation. It doesn’t mean the company becomes bad, but rather all upside is priced in and future......
(read more)August 22 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling......
(read more)August 19 - News - Comments
When a company is acquired, the acquirer pays a large premium to where the acquired company’s stock price had previously been trading. Because of this......
(read more)August 13 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July. But can a deal give......
(read more)August 6 - News - Comments
In 2013, a number of new drugs got approvals from the FDA. This provided a boost to the biotech industry as a whole. Now, this speculative growth market......
(read more)August 5 - News - Comments
In the last couple of months, we saw two big offers being made – and rejected – in the biotech sector. Both times, the companies that rejected......
(read more)August 5 - News - Comments
With the SPDR S&P Biotech Index up 43% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......
(read more)August 5 - News - Comments
There are few times when your doctor or physician will utter the phrase, “I don’t know” to a patient, but when you’re dealing......
(read more)August 5 - News - Comments
Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors.......
(read more)July 29 - News - Comments
The biotech industry is known for fast paced acquisitions and rapid market consolidation. Larger pharmaceutical companies headed towards patent cliffs......
(read more)July 29 - News - Comments
You may or may not have heard, but it’s earnings season again. Contrary to popular belief, earnings season does actually take a break for a few......
(read more)July 22 - News - Comments
In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations......
(read more)July 19 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I’d be unable to keep up on......
(read more)July 18 - News - Comments
Buyout! The word gets biotech investors’ blood flowing and their hearts racing. Mere rumors that a biotech stock could get bought out can send shares......
(read more)July 17 - News - Comments
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has a particularly fascinating history, having been at the center of controversy for the better part of its......
(read more)July 17 - News - Comments
Celldex Therapeutics, Inc. (NASDAQ:CLDX), the first antibody-based immunotherapy company, has been a strong buy recommended by several analysts for some......
(read more)July 17 - News - Comments
According to a Bloomberg report, Roche is prepared to offer $130 a share to purchase Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). In other words, Roche......
(read more)July 15 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling......
(read more)July 15 - News - Comments
With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......
(read more)July 15 - News - Comments
Orphan drug companies are an exciting new class in the healthcare sector — with good and bad investment opportunities — let’s look at......
(read more)June 28 - News - Comments
It’s truly been a bizarre day, with the broad-based S&P 500 (INDEXSP:.INX) rallying in excess of 1% after economic data came in worse than expected......
(read more)June 26 - News - Comments
